Rilvegostomig With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Short Title: ARTEMIDE

Enrollment Status: Recruiting

NCT #: NCT06764875

Specialty Area: Oncology

Condition Studied: Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To find out how well rilvegostomig works when combined with chemotherapy and other cancer medications for people with HER2-positive stomach or GEJ cancer.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with HER2-positive, PD-L1 CPS ≥ 1 gastric or GEJ adenocarcinoma
Cancer must have moved into nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic)
No prior treatment for advanced disease

What's Involved

Participation in the study will include:

Treatment given intravenously (IV) or orally with one of the following combinations:
rilvegostomig + fluoropyrimidine + trastuzumab deruxtecan
trastuzumab + chemotherapy + pembrolizumab
rilvegostomig + trastuzumab + chemotherapy
Chemotherapy given intravenously (IV) or orally may include 5-fluorouracil, capecitabine, cisplatin, or oxaliplatin
CT scans to monitor response to treatment
Blood tests to monitor your health and treatment effects
Questionnaires

Principal Investigator

Katharine Thomas, MD

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06764875

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews